Bimekizumab is effective for active psoriatic arthritis in biologic-naïve adults
1. Significantly more patients in the bimekizumab group reached ACR50 at week 16 compared to the placebo. 2. Fungal infections ...
Tag: Biologic disease-modifying anti-rheumatic drugs (bDMARDs
Tofacitinib increases cardiovascular and cancer risk in rheumatoid arthritis
1. Patients with rheumatoid arthritis (RA) treated with tofacitinib showed a higher risk of developing major adverse cardiovascular events and ...
A Comparison of Psoriasis Severity in Pediatric Patients Treated With Methotrexate vs Biologic Agents
1. Treatment with biologics in pediatric patients with moderate to severe psoriasis was significantly associated with greater reduction in psoriasis ...
#VisualAbstract: Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X)
1. Ixekizumab, an IL-17 inhibitor, elicits disease response in patients with non-radiographic active axial spondyloarthritis who have failed treatment with ...
Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X)
1. Ixekizumab, an IL-17 inhibitor, elicits disease response in patients with non-radiographic active axial spondyloarthritis who have failed treatment with ...